LianBio Overview
LianBio (LIAN) has a ROE of -43.48%, below the sector sector average of -5.87%.
Get informed when a big investor buys or sells
+ Follow-43.48%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for LIAN is -43.48%. That is below the sector sector average of -5.87%. Investors often review this figure alongside LianBio's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, LIAN currently prints -43.48% for ROE, while the sector average sits near -5.87%. That is roughly 640.9% below the sector mean. Large gaps often invite a closer look at LianBio's growth, margins, and balance sheet.
Return on Equity shows how effectively LianBio converts resources into returns. At -43.48%, LIAN may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting LIAN's ROE (-43.48%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
